UCB SA (FRA:UNC)

Market Cap	42.60B
Revenue (ttm)	6.85B
Net Income (ttm)	1.33B
Shares Out	n/a
EPS (ttm)	6.87
PE Ratio	31.98
Forward PE	24.94
Dividend	0.97 (0.45%)
Ex-Dividend Date	Apr 25, 2025

Volume	n/a
Average Volume	50
Open	229.10
Previous Close	221.20
Day's Range	229.10 - 229.10
52-Week Range	135.90 - 260.90
Beta	n/a
RSI	49.10
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,378
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UNC

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.